摘要
目的探讨拉帕替尼联合白蛋白结合型紫杉醇在曲妥珠单抗治疗失败的HER2阳性的晚期乳腺癌的有效率及安全性。方法选择15例曲妥珠单抗治疗失败的晚期乳腺癌患者。治疗方案：白蛋白结合型紫杉醇130mg/m2、8、15及21d为1个周期，共2—8个周期；同时给予拉帕替尼1250mgqd治疗至疾病进展。结果15例均可评估。客观缓解率46．6％（7／15），部分缓解（paaial response，PR）7例（46．6％），病情稳定（stable disease，SD）4例（26．7％），肿瘤进展（progressive disease，PD）4例（26．7％）。中位随访时间9个月。中位无进展生存期（median progression-free survival，mPFS）为8个月。主要的3／4级不良反应为中性粒细胞减少33-3％（5／15），腹泻20．0％（3／15）、皮疹20．0％（3／15）、肝功能损害13.3％（2／15）。结论拉帕替尼联合白蛋白结合型紫杉醇治疗曲妥珠单抗治疗失败的HER2阳性乳腺癌的客观缓解率高，耐受性良好。
Objective To investigate the efficiency and safety of lapatinib combined with albumin-bound paclitaxel in human epidermal growth factor receptor-2 （HER2） positive advanced breast cancer with progressive disease （PD） during treatment with trastuzumab. Methods 15 cases of advanced breast cancer with PD during treatment with trastuzumab were selected. The treatment schemes were as the following： albumin-bound paclitaxel 130 mg/m2 D1, 8, 15, 21 days for a cycle, a total of 2 to 8 cycles, and combined with lapatinib 1250 mg QD until PD. Results All the 15 cases can be evaluated. Objective remission rate was 46.6% （7/15）, partial remission （PR） was in 7 patients （46.6%） , stable disease （SD） was in 4 patients （26.7%）, and progressive disease （PD） was in 4 patients. The median progression-free survival （mPFS） was 8 months after a median follow-up of 9 months. The main grade 3/4 adverse reactions included neutrophile granulocyte decreasment（33.3%, 5/15）, diar- rhea 20% （3/15）, rash 20% （3/15）, and liver function damage 13.3% （2/15）. Conclusion Lapatinib combined with albumin-bound paclitaxel has a high objective response rate and well toleration in HER2 positive breast cancer with PD during treatment with trastuzumab.
作者
李娜妮
刘健
吴凡
林小敏
Li Nani Liu Jian Wu Fan Lin Xiaomin(Department of Medical Oncology, Fujian Provincial Cancer Hospital, the Teaching Hospital of Fujian Medical U- niversity, the Teaching Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou 350014, China)
出处
《中华内分泌外科杂志》
CAS
2016年第5期369-373,共5页
Chinese Journal of Endocrine Surgery
基金
福建省自然科学基金资助项目（2015J01381）
